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Abstract
There is huge global concern surrounding the emergence of antimicrobial resistant bacteria and this is 
resulting in an inability to treat infectious diseases. This is due to a lack of new antimicrobials coming 
to the market and irresponsible use of traditional antibiotics. Bactofencin A, a novel antimicrobial 
peptide which shows potential as an antibiotic, is susceptible to enzyme degradation. To improve its 
solution stability and inherent activity, bactofencin A was loaded onto a traditional silica mesoporous 
matrix, SBA-15, and a periodic mesoporous organosilane, MSE. The loading of bactofencin A was 
considerably higher onto SBA-15 than MSE due to the hydrophilic nature of SBA-15. While there was 
no detectable peptide released from SBA-15 into phosphate buffered saline and only 20 % of the 
peptide loaded onto MSE was released, the loaded matrices showed enhanced activity compared to 
the free peptide during in vitro antimicrobial assays. In addition, the mesoporous matrices were found 
to protect bactofencin A against enzymatic degradation where results showed that the SBA-15 and 
MSE with loaded bactofencin A exposed to trypsin inhibited the growth of S. aureus while a large 
decrease in activity was observed for free bactofencin upon exposure to trypsin. Thus, the activity and 
stability of bactofencin A can be enhanced using mesoporous matrices and these matrices may enable 
its potential development as a novel antibiotic. This work also shows that in silico studies looking at 
surface functional group and size complementarity between the peptide and the protective matrix 
could enable the systemic selection of a mesoporous matrix for individual bacteriocins with potential 
antimicrobial therapeutic properties.
  
Introduction
The number of new antimicrobial drugs being brought to the market has declined rapidly over the 
past decade and this coupled with the non-prudent use of existing antibiotics has led to the emergence 
of antibiotic resistant bacteria (Cansizoglu and Toprak 2017). There is huge global concern surrounding 
the emergence of these bacteria as they are resulting in an inability to treat infectious diseases. This 
will have huge impact on our health services both now and into the future if this problem is not 
addressed immediately (Cavera et al. 2015). It is estimated that antimicrobial resistance (AMR) could 
cause 10 million deaths a year by 2050 (O'Neill 2014). Many of the old reliable antibiotics are now 
becoming ineffective and it is thought that there are only two solutions to this problem; repurposing 
existing therapeutic drugs or the discovery of new antimicrobial molecules. Unfortunately, 
pharmaceutical companies appear to be more focussed on treatments for metabolic and chronic 
disease drugs due to the more profitable nature of these products than in developing new antibiotics 
(Fernandes and Martens 2017). 
Antimicrobial peptides are one such biological product that could be a means to tackle this 
overwhelming issue. There have been a number of antimicrobial peptides identified for their activity 
against both Gram-positive and Gram-negative bacteria (Hancock and Sahl 2006, O'Shea et al. 2013) 
including Streptococcus pneumoniae, staphylococci (including methicillin-resistant Staphylococcus 
aureus (MRSA)), vancomycin-resistant enterococci (VRE), various mycobacteria, and Clostridium 
difficile. These peptides generally have a high potency and low toxicity and have the advantage of 
being produced by microorganisms or bio-engineered (Cotter et al. 2013). They also exhibit anti-viral, 
anti-fungal and anti-cancer activity but this study will focus on their role as potential antibiotics (Li et 
al. 2012). To-date there is only one antimicrobial peptide mimic in clinical trials called brilacidin. 
Brilacidin (Medicine 2018), with a molecular weight of less than 1 kDa is currently in phase 2 of clinical 
trials in the US and has shown activity towards a range of Gram-positive and Gram-negative pathogens 
including some drug and multidrug resistant strains (Mensa et al. 2014). The use of brilacidin to treat 
acute S. aureus skin infections is being reviewed. 
A key emerging group of antimicrobial peptides include the bacteriocins which are produced by Lactic 
Acid Bacteria (LAB). Bacteriocins are ribosomally synthesized hydrophobic peptides which usually 
display activity towards bacteria closely related to the producer (Lozo et al. 2017) and may be 
subdivided based on whether or not they have undergone post translational modifications (Class I) or 
  
not (Class II).  This group of antimicrobial peptides exhibit enhanced potency, are biocompatible and 
stable and can have a narrow or broad range spectrum of activity (Cotter et al. 2013). Bacteriocins are 
known to possess antimicrobial activity towards pathogens present in the GI tract so could therefore 
provide an alternative to antibiotics currently used to treat infections in this area (O'Shea et al. 2009). 
In addition, all LAB and their products are generally regarded as safe (GRAS) by the US Food and Drug 
Administration (FDA)(Acedo et al. 2017). 
These peptides have a different mode of action when compared with traditional antibiotics therefore 
minimising the potential for the emergence of antibiotic resistance. There are a number of studies 
carried out on the antibacterial properties of a range of various bacteriocins including nisin, thuricin 
CD & lacticin 3147. Nisin and lacticin 3147 exhibit activity against a range of bacterial strains including 
S. pneumonia, MRSA, VRE, various mycobacteria and C. difficile and thus are potential therapeutics 
for hospital acquired infections (Cotter et al. 2013, Flynn et al. 2018). Nisin, a lantibiotic produced by 
Lactococcus lactis (Okuda et al. 2013), is FDA-approved as a food additive (E234) and is certified as a 
GRAS (Generally Regarded as Safe) excipient. Nisin has been shown to be more effective as a 
treatment for S. pneumonia in mice than vancomycin (Field et al. 2010). Thuricin CD is an example of 
a narrow-spectrum sactibiotic bacteriocin which targets spore forming Gram-positive bacteria 
including C. difficile (Mathur et al. 2017). This bacteriocin has a very narrow spectrum of activity and 
could be used specifically to treat C. difficile infections of the gut. (Acedo et al. 2017, Ahn et al. 2017, 
Lozo et al. 2017). Enterocin NKR-5-3, a class IIa bacteriocin, shows potent activity against Listeria spp. 
(O’Connor et al. 2015) and various bacteriocins have exhibited antifungal properties and can kill spores 
associated with sporeforming bacteria (Cavera et al. 2015). All this highlights the relevance of 
bacteriocins as clinical therapeutics and as an alternative to traditional antibiotic use. Antimicrobial 
peptides which display a broad spectrum of activity can cause irregularities to the commensal 
microbiota of the gut. Therefore bacteriocin therapeutics with narrow spectrum activity could prove 
more useful. There is evidence that C. difficile infections can lead to gut irregularities and the resulting 
symptoms may need further treatment by antibiotics. In this case a narrow spectrum therapeutic i.e. 
thuricin CD can target the bacteria without disrupting the resident microbiota (Cotter et al. 2013). 
Bactofencin A belongs to the Class II lactic acid bacteria group and is a cationic bacteriocin produced 
by the porcine intestinal isolate Lactobacillus salivarius DPC6502. It is a linear peptide of 22 amino 
acids long that bears a close resemblance to other eukaryotic cationic antimicrobial peptides (O'Shea 
et al. 2013). It is known to exhibit both a narrow spectrum and a broad spectrum of inhibition against 
a variety of Gram-positive bacteria including Listeria spp., Lactobacillus spp. and S. aureus. One of the 
advantages to the use of bactofencin A is that it can be produced synthetically (O’ Connor et al. 2018) 
  
and due to its unmodified nature, controlled large quantities can be generated. It has also been 
reported by Guinane et al., that the use of a bacteriocin like Bactofencin A can enhance the overall 
health of the gut microbiota (Guinane et al. 2016), a common issue reported after treatment with 
traditional antibiotics.
However, the use of bacteriocins as antibiotics can be hampered by low solubility, slow dissolution 
rates, susceptibility to proteolytic enzymes and/or their propensity to aggregate in vivo or during 
formulation and storage (Aguirre et al. 2016). Manipulation of these factors at the pre-formulation 
step or by using delivery systems can help to overcome these issues. There are various delivery 
systems for large biomolecules, for example the use of oily suspensions, enteric coated tablets, 
hydrogels, biodegradable nanoparticles and liposomes for oral delivery of peptides and proteins (Jung 
et al. 2000, Watkins and Chen 2015, Moroz et al. 2016, Buwalda et al. 2017, Meikle et al. 2017). The 
delivery of Octreotide, a synthetic hormone used to regulate the neuroendocrine system using a novel 
oily suspension with sodium caprylate was investigated and results showed an increase in paracellular 
permeability in monkeys with this suspension (Tuvia et al. 2014). Another peptide, Calcitonin which is 
frequently administered to regulate calcium homeostasis is generally administered via the parenteral 
or nasal routes (Moroz et al. 2016). Its administration via the oral route has also been investigated 
using a formulation of enteric coatings containing citric acid. The presence of the acid caused a 
decrease in the pH of the intestine therefore rendering the resident intestinal and pancreatic enzymes 
redundant and subsequently permeability was enhanced (Binkley et al. 2012). The use of hydrogels as 
drug delivery systems can protect against the harsh environment (enzymes and low pH) of the GI tract 
(Qiu and Park 2001). Another gel delivery system , a sodium dodecyl sulfate (SDS)/β-cyclodextrin (β-
CD)/chitosan gel has been shown to offer protection to insulin against pepsin in vitro (Li et al. 2016). 
Other relevant delivery matrices for encapsulation of peptides include the use of mesoporous 
matrices (Braun et al. 2016, Braun et al. 2017, Xie et al. 2017, de la Torre et al. 2018). Mesoporous 
matrices have large surface areas and well defined pore structures (Chaudhary and Sharma 2017). 
They can be designed to have straight narrow channels with high surface areas which can allow for 
the adsorption of large amounts of various drugs, including proteins and peptides (Hudson et al. 2008). 
These silica matrices contain a large number of hydroxyl groups which may be readily functionalised 
post synthesis or the matrix can be functionalised using organosilanes, either as bridging or non-
bridging precursors, during synthesis. This functionalisation can control the rate of adsorption and 
release of drugs. The matrices are often structurally stable upon storage and are resistant to heat, 
changes in pH, mechanical stress and degradation (McCarthy et al. 2016). However, the mechanisms 
of drug release and adsorption depend on the size and chemistry of the adsorbed molecule and the 
  
chemical composition, the pore structure and the pore size of the mesoporous matrix (McCarthy et 
al. 2017). Two mesoporous matrices were investigated during this study, SBA-15 and MSE, as potential 
carriers for bactofencin A. SBA-15 is a highly ordered hexagonal pure mesoporous silica (Zhao et al. 
1998), whereas MSE involves using an ethylene-bridged silica precursor to form a mesoporous matrix 
with ethane groups periodically and homogeneously distributed throughout the pores in an ordered 
manner (Bao et al. 2004). It has been reported that pure silica materials (i.e. SBA-15) are 
biocompatible, although there may be some issues if they reach the blood stream (Lu et al. 2007, 
Hudson et al. 2008). Less is known about MSE because of the lack of in vitro and in vivo research on 
this material (Du et al. 2016). There have been numerous reports on the loading of mesoporous 
silicates with various anti-cancer drugs i.e  doxorubicin, topotecan & camptothecin (Luo et al. 2014), 
anti-inflammatory drugs i.e. ibuprofen (Charnay et al. 2004) and poorly water soluble drugs i.e. 
telmisartan (Zhang et al. 2010). However fewer studies have been carried out on peptide loading onto 
mesoporous matrices. A previous study from our group showed that pore size and chemical 
functionality had an effect on loading and release of nisin A from mesoporous matrices. This study 
also highlighted the protective nature of a mesoporous matrix against enzymatic degradation of nisin  
while retaining activity (Flynn et al. 2018).
In this present study we investigate the loading of the novel antimicrobial peptide, bactofencin A onto 
SBA-15 and MSE. In addition the activity of the loaded matrices against S. aureus, the biocompatibility 
of both matrices against Human Embryonic Kidney (HEK293) cells and the role of the matrices in 
protecting the bacteriocin against proteolytic enzymes found in vivo were examined.  
Materials & Methods
Materials
Staphylococcus aureus culture (DSMZ 20231) was purchased from DSMZ.  Human Embryonic Kidneys 
(HEK293) cells were gifted to our research group by Dr. Pat Kiely’s Research Group, Graduate Entry 
Medical School, University of Limerick. Brain Heart Infusion (BHI) broth and agar, and isopropanol 
were obtained from Fisher Scientific. Acetonitrile (ACN), trifluoroacetic acid (TFA), hydrochloric acid 
(37 %), DMEM high glucose media (D6429), fetal bovine serum (FBS), trypsin/EDTA, 
penicillin/streptomycin, phosphate buffered saline (PBS), proteinase K and trypsin were all obtained 
from Sigma.  MTT cell assay kits were obtained from Merck Millipore (CT02). Synthetic bactofencin A 
was provided to us from our collaborators in Teagasc Food Research Centre, Moorepark, Cork, Ireland.
Synthesis of Bactofencin A
  
Synthetic Bactofencin A was used throughout this study. Peptide was synthesised on an H-Cys (Trt)-
HMBP pre-loaded resin using microwave-assisted solid phase peptide synthesis (MW-SPPS) performed 
on a Liberty Blue microwave peptide synthesizer (CEM Corporation. Mathews, North Carolina, USA). 
Crude peptide was purified using RP-HPLC on a Semi Preparative Jupiter Proteo (4µ, 90Å) column 
(Phenomenex, Cheshire, UK) running a 15-35% acetonitrile 0.1% TFA gradient over 40 minutes where 
buffer A is Milli Q water containing 0.1% TFA and buffer B is 90% acetonitrile 0.1% TFA. Fractions 
containing the desired molecular mass were identified using matrix assisted laser deionisation -time 
of flight-mass spectrometry (MALDI-TOF-MS) on an Axima TOF2 MALDI TOF mass spectrometer 
(Shimadzu Biotech, Manchester, UK) and were pooled and lyophilized on a Genevac HT 4X lyophilizer 
(Genevac Ltd., Ipswich, UK) (O’ Connor et al. 2018).
To estimate the dimensions of Bactofencin A, calculations using the amino acid sequence with the 
disulphide bridge were carried out with Materials Studio version 7.0 from Accelrys Inc., and the 
COMPASS II force field, applicable for organic molecules, including heterocyclic systems (Sun 1998).
Synthesis of SBA-15 and MSE
SBA-15 and MSE were synthesised and characterised by solid state nuclear magnetic resonance 
spectroscopy, scanning and transmission electron microscopy, X-ray diffraction, nitrogen adsorption 
analysis and attenuated reflectance Fourier transform infra-red spectroscopy according to previously 
published protocols (Sayari et al. 2004, Bao et al. 2006, Flynn et al. 2018). 
Adsorption/Release of Bactofencin A onto two Mesoporous matrices (SBA-15 & MSE).
Samples were UV sterilised x 30 minutes and 5mg of each MPS was added to 1mL of a sterile 0.5 
mg/mL solution of bactofencin A (in 50mM sodium phosphate buffer pH 6.8) and mixed until the 
sample was homogenous. Sterility was maintained from this point forward for activity studies to 
follow. These mixtures were incubated on a rocker at 37ºC x 2 hours. After this incubation time, 
samples were centrifuged at 5000rpm x 15 minutes. The supernatant was removed and analysed by 
HPLC to determine the amount of bactofencin A remaining in the supernatant and subsequently the 
loading concentration of the bactofencin A onto the mesoporous matrices. A control was set up of 
1mL of a 0.5mg/mL solution of bactofencin A and this was also incubated for the same time under the 
same conditions. After the supernatant was removed, the pellets were allowed to dry in a biological 
safety cabinet (BSC) to maintain sterility. In order to investigate the release of bactofencin A from the 
MPS, 1mL of sterile PBS was added to the dried pellets in a 1.5mL tube. Solutions were mixed to ensure 
the pellets were in suspension with the PBS and these were incubated, rocking at 37ºc x 24 hours. At 
each analysis timepoint (2, 4, 6 & 24 hrs), the tube was centrifuged at 5000rpm x 15 minutes, 
  
supernatant was removed, ensuring the MPS/bactofencin A pellet does not come away with the 
supernatant. The tube was replenished with 1mL of fresh sterile PBS and vortexed until a homogenous 
mixture was obtained. The supernatant was kept for analysis by HPLC where the amount of peptide 
released at each timepoint was determined. Pellets were allowed to dry in a BSC after the release 
assay. Analysis was carried out in triplicate on two random testing days.
HPLC determination of Bactofencin A
The HPLC determination of bactofencin A concentration was carried out using an Agilent Infinity 1260 
HPLC/MS and a Phenomenex C18 Gemini (5um, 110Å, 250 x 4.6mm) column. The mobile phase used 
was A: MilliQ H2O with 0.1% TFA and B: 90% ACN with 0.1% TFA. A gradient elution was set up as 
follows: concentration of B increased from 10 to 30% from 5 to 45 minutes. From 45 to 50 minutes 
the concentration of B increased to 81% and returned to 10% until 55 minutes. 20µl of sample was 
injected and the flow rate was 0.8mL/minute. The presence of bactofencin A was detected by 
absorbance at 214nm. Concentrations of bactofencin A and hence % loading and release was 
calculated as a % of the peak area (RT:~25 mins) of the control.
MIC50 of Bactofencin A against S. aureus
Bactofencin A was dissolved in 50mM sodium phosphate, pH 6.8 at a concentration of 1mg/mL. A 
microtitre assay using 96 well plates was used to determine an MIC50 against S. aureus (DSMZ 20231). 
Overnight culture was grown at 37ºC, shaking at 250rpm. Microtitre assays were set up in triplicate in 
96 well plates as follows: 200µl of BSA (0.1% in PBS) was added to each well and incubated x 30 
minutes at 37ºC in order to prevent the peptide adhering to the sides of the well (O'Shea et al. 2013). 
After 30 minutes wells were washed with PBS and allowed to dry. Varying concentrations of peptide 
(0.5-5ug/mL) were added to the test wells first, followed by 50mM sodium phosphate buffer to make 
up a volume of 50µl. Overnight culture was diluted to an optical density (OD) of 0.1 using BHI broth 
and monitored at 590nm. 150µl of the diluted culture was then added to each well. A control was set 
up with 50ul of buffer and 150µl culture. Blanks (media only) were also set up on the same plate. Each 
sample, blank and control was set up in triplicate. Plates were incubated in a Biotek ELx808 Ultra 
microplate reader (Mason Technologies, Dublin, Ireland) and OD590 was monitored with mild shaking 
before each reading. Readings were taken every 30 minutes over a 24 hour period. Blank readings 
were subtracted from readings in the test well. MIC50 was determined as the concentration of 
bactofencin A required to kill 50% of the bacterial population after 24 hours. Results include two 
random tests of triplicates.
  
Bioactivity of peptide loaded MPS against S. aureus
An overnight culture of S. aureus was grown up in BHI broth. This culture was diluted to an OD of 0.1 
after ~ 16 hours with BHI broth. Similar to the loading study outlined previously, MPS were loaded 
with bactofencin (0.5 mg bactofencin per 5 mg MPS) for 2 hours. Following this loading period the 
suspension was centrifuged at 5000 rpm x 10 mins and the supernatant was removed. Pellets were 
allowed to dry in a biosafety cabinet for 1-2 hours. The dried mesoporous silicate pellets with adsorbed 
bactofencin A were transferred to 3mL of the diluted bacterial culture and were incubated for 5 hours 
at 37ºC. Incubation time of 5 hours was chosen as this is the time point where decline in bacterial 
numbers when incubated with the peptide was evident due to nutrient depletion during MIC50 tests.  
Controls were set up with (a) bactofencin A (0.5 mg/ 3 mL diluted cell culture) only and (b) MPS 
(5mg/3mL diluted cell culture) only. After 5 hours, serial dilutions were made in PBS and plated onto 
BHI plates. Plates were incubated at 37ºC for 24 hours and colonies were counted and expressed as 
colony forming units (CFU) per mL. Results include two random tests of duplicates.
Enzyme degradation of Bactofencin
The susceptibility of bactofencin A to degradation by two enzymes was investigated. A 1mg/mL 
solution of trypsin or proteinase K and a 1mg/mL solution of bactofencin A (50mM Sodium Phosphate 
pH 6.8) were mixed in a 5: 1 (Peptide:Enzyme) ratio. This mixture was incubated at 37ºC with rocking 
for 24 hours, acidified to pH 2 using 1M HCl to stop the enzyme activity and analysed using HPLC.
Protection against enzyme degradation
Bactofencin A was loaded onto both MSE and SBA-15 as described previously. After removal of the 
supernatant, the pellets were allowed to dry for 1-2 hours under sterile conditions and 200µl of trypsin 
(1mg/mL) was added to the pellets and allowed to incubate rocking for ~16 hours at 37ºC. A control 
was set up with bactofencin A (1mg/mL) and trypsin (1mg/mL) in the ratio 5: 1 (Peptide:Enzyme) and 
also allowed to incubate rocking for ~16 hours at 37ºC. Following incubation, samples were 
centrifuged at 5000rpm x 10mins, washed with DI H2O and centrifuged again. Supernatant was 
removed and the pellet was allowed to incubate with 3 mL of S. aureus (OD = 0.1) for 5 hours. A control 
solution of bactofencin A and trypsin (100ul) was also added to 2.9mL of culture for 5 hours. After this 
time, serial dilutions of test samples and controls were made in PBS and plated onto BHI plates. These 
plates were allowed to incubate overnight at 37ºC and colonies were counted and expressed as 
CFU/mL. Analysis was carried out in duplicate on two random testing days.
  
Biocompatibility of MPS with HEK293 cells using In Vitro cell assays
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium) assays were carried out on mammalian 
HEK 293 (Human embryonic kidney) cells to ascertain the compatibility of the matrices with 
mammalian cells. Cells were maintained in DMEM media with 10% FBS, 1% Penicillin/Streptomycin 
and 1% L-glutamine. Cells were incubated at 37ºC, 5% CO2 and 95% relative humidity. Passage 
numbers less than 30 were routinely used for the MTT assays. 10,000 cells per well were seeded in a 
96 well plate. Cells were incubated overnight to ensure adherence of the HEK293 cells. The matrices 
were UV sterilised for 30 minutes. Media was changed in the wells before addition of the matrix. A 
stock suspension of 50mg/mL of matrix in PBS was prepared and sonicated for 1 hour to achieve a 
homogenous sample. Stock solutions of samples were added to each well to give a final concentration 
of 1, 3 & 5 mg/mL and the matrix was incubated with the cells for 2, 6 & 24 hours. Live controls with 
buffer (50mM sodium phosphate pH 6.8) were set up in addition to dead controls which were treated 
with 10% Triton-X. Blank media with matrices were also set up to ensure the matrices did not interfere 
with readings. After the  incubation period, MTT reagent was added (10µl) to each well and allow to 
incubate for a further 4 hours. After 4 hours, 100µl isopropanol with 0.1 M HCl was added to each well 
according to manufacturer’s instructions, plates were centrifuged at 1000rpm x 5mins and the 
supernatant (100 µl)  was transferred to a new 96 well plate. Plates were read at 570 nm and test 
results were expressed as % cells that were viable after treatment when compared with the live 
control. Analysis was carried out in triplicate on two random testing days.
Results and Discussion
Adsorption/Release of Bactofencin A onto Mesoporous silicates (SBA-15 & MSE).
Bactofencin contains 22 amino acids, has a molecular mass of 2,782 Da and contains two cysteine 
residues that form an intramolecular disulfide bond. It is a cationic peptide with an isoelectric point of 
10.59 (O'Shea et al. 2013). This means that it will have an overall positive surface charge in solution at 
pH values less than this. While the crystal structure of bactofencin is not yet known, using Materials 
Studio to estimate its size, the largest possible dimensions of bactofencin are 22 Å x 27 Å x 30 Å. 
Both mesoporous matrices used in this study (SBA-15 and MSE) were characterised extensively by our 
group in a recent publication (Flynn et al. 2018). Both matrices have ordered hexagonal pore 
structures with pore sizes of 68 Å for SBA-15 and 60 Å for MSE. Given the predicted size of bactofencin 
A, it should fit inside the pores of both of these matrices. SBA-15 and MSE have isoelectric points of 
3.7 and 4.8 (Flynn et al. 2018). Therefore, at pH 6.8 these matrices will be negatively charged. MSE 
contains additional hydrophobic ethane groups in its framework as well as hydrophilic silanol groups 
  
and thus can enable adsorption through hydrophobic or hydrophilic interactions. SBA-15 however 
contains predominantly hydrophilic silanol groups on its surface with a small percentage of the slightly 
more hydrophobic siloxane bridges and thus hydrophilic interactions would be expected to dominate. 
Thus if electrostatic interactions dominate during adsorption, bactofencin would adsorb onto both 
SBA-15 and MSE. Bactofencin is composed of 10 hydrophilic amino acids and 5 hydrophobic amino 
acids. While we cannot estimate which of these amino acids are exposed on the surface of the peptide 
without its tertiary structure, the higher percentage of hydrophilic groups would suggest that it might 
bind preferentially to SBA-15 than MSE. In our previous study, nisin, which contains a high proportion 
of hydrophobic residues, bound preferentially to MSE over SBA-15 (Flynn et al. 2018). 
From the adsorption studies, bactofencin A loading was indeed found to be considerably higher onto 
SBA-15 than MSE, giving a loading of 93ug and 34ug of bactofencin respectively per mg of MPS (Figure 
1). The lower loading onto MSE may be due to the hydrophobic nature of the MSE material. It has 
been reported that enhanced loading is possible when the pore size of a mesoporous silicate (MPS) is 
slightly larger than the protein/peptide and when the charges on the MPS and the peptide are 
complimentary (Deere et al. 2003). Deere at al. studied the loading of cytochrome C onto MPS and a 
pore size slightly larger than the protein and the complimentary surface charges of the protein and 
the matrix were vital for high loading. Functionalisation of the mesoporous matrix with more 
hydrophobic groups did not enhance loading of the peptide, indicating that bactofencin preferentially 
adsorbs to a more hydrophilic surface and hydrogen bonding or electrostatic interactions dominate 
over hydrophobic interactions. Unfortunately complete adsorption isotherms could not be generated 
due to a limited supply of bactofencin A.
When the release of bactofencin A from both MPS was monitored into PBS using RP-HPLC over 24 
hours, no release was observed from SBA-15. As discussed previously, bactofencin A is a cationic 
peptide and the presence of the negatively charged –OH groups in the SBA-15 may result in strong 
electrostatic interactions between peptide and the material preventing leaching of the bactofencin A. 
There are less OH groups present on the surface of MSE (Flynn et al. 2018) so this indicates a lower 
degree of electrostatic interactions between peptide and material and therefore a reduced loading, a 
weaker binding and thus an increased rate of release were observed. A burst release of bactofencin A 
from MSE was observed up to 6 hours and 20 % or ~ 6ug/mL of the adsorbed bactofencin was released 
in total (Figure 2a & b). The release of the peptide from the matrix is through diffusion through the 
ordered pores due to the insoluble nature of the matrices at neutral pH (Balas et al. 2006). The loading 
of a number of antibiotics on MPS has been studied in the past and the efficacy of SBA-15 silica-based 
bioceramics as a drug delivery system with vancomycin, rifampicin and linezolid, either alone or in 
  
combination has been confirmed and controlled antibiotic release was achieved (Molina-Manso et al. 
2012). 
MIC50 of Bactofencin A against S. aureus
During this study the antibacterial effect of bactofencin A against S. aureus was examined. The MIC50 
with S. aureus was determined to be 5ug/mL (Figure 3).  It has been reported in a previous study by 
O’ Shea et al. (O'Shea et al. 2013) that bactofencin concentrations of 1-5uM were sufficient to inhibit 
the growth of S. aureus. These concentrations equate to the range 14-28ug/mL but in this work, much 
lower bactofencin A concentrations have similar outcomes. Bactofencin A contains a large percentage 
of the basic residues arginine and lysine at the N terminal and it is thought that this basic charge on 
the peptide allows for electrostatic interactions with the negatively charged bacterial cell membrane 
(O'Shea et al. 2013), therefore causing inhibition of bacterial growth. Other bacteriocins, e.g. nisin A 
and lacticin 3147, have shown similar trends against S. aureus and other Gram-positive bacteria 
Bioactivity of peptide loaded MPS against S. aureus
The level of bacterial growth was greatly inhibited when the bactofencin A loaded SBA-15 & MSE 
(loaded with 0.47 mg and 0.17 mg of bactofencin respectively) were incubated with a culture of early 
log phase S. aureus, by 87% and 69%, respectively (Figure 4). This was a higher antimicrobial activity 
than the free bactofencin control which contained 0.5 mg of bactofencin and inhibited the same 
culture by only 51%. This would suggest that the bactofencin A loaded onto the matrices is more active 
than free bactofencin A. This enhanced activity could be due to the presence of some of the adsorbed 
peptide on the outer surface area of the matrices, making more of the peptide available and/or due 
to increased contact time between bactofencin A and the bacteria. It is also feasible that in the 
environment of the culture, bactofencin is deactivated to some extent, accounting for the lower 
activity of the free bactofencin in the control compared to the bacteriocin adsorbed onto the matrices. 
While a greater inhibition was noted with SBA-15 loaded particles over MSE loaded particles, this may 
be due to the higher loading of bactofencin in this sample. Taking the loading into account, the 
greatest antimicrobial activity per mg of bactofencin present was observed for the MSE/bactofencin 
A sample. MSE or SBA-15 by itself demonstrated no antimicrobial activity against S. aureus. 
Bactofencin A releases into PBS from the MSE matrix but not from SBA-15 but it is feasible that it is 
released from both matrices in the media used in the activity assay. This may happen at a faster rate 
from MSE, where the interaction between bactofencin and its surface appears to be weaker and 
results in a higher specific activity. 
  
Protective nature of MPS against proteolytic degradation of Bactofencin A 
In order to probe if the mesoporous matrix of SBA-15 and MSE does indeed protect bactofencin A 
from degradation, a proteolytic degradation study was conducted. The proteolytic degradation of 
proteins and peptides is one of greatest stumbling blocks to their therapeutic use. Degradation by the 
serine endopeptidases trypsin, chymotrypsin and elastase is a huge issue surrounding the oral delivery 
of peptides or proteins. Ordered porous silicates used as drug delivery matrices have been shown to 
protect antimicrobial peptides and enzymes from proteolytic degradation (Kim et al. 2007, Braun et 
al. 2016) and therefore maintain their antimicrobial properties. During this study we investigated the 
role of trypsin on the cleavage of bactofencin A. Trypsin cleaves at the C terminal of arginine and lysine 
residues and as ~30% of bactofencin A is made up of these basic residues, this peptide is highly 
susceptible to degradation (Olsen et al. 2004). The use of delivery matrices to protect these 
biomolecules in vitro is one method which may be used to overcome this issue. Results in the present 
study demonstrated that bactofencin A is susceptible to degradation by the luminal proteases trypsin 
and proteinase K (Figure 5). HPLC analysis shows significant differences in the profile of free 
bactofencin A and digested bactofencin A. The intact peptide peak was no longer present after 
digestion with either trypsin or proteinase K, but rather replaced by numerous smaller peaks. When 
free bactofencin A (not adsorbed to a porous matrix) was exposed to trypsin and digested it only 
inhibited growth of S. aureus by 8% whereas undigested bactofencin A inhibited growth by 51% (Figure 
4 & 6). Therefore digestion by trypsin rendered the peptide almost totally inactive. SBA-15 and MSE 
with loaded bactofencin A exposed to trypsin inhibited the growth of S. aureus by 64 and 29% 
respectively (Figure 6) while the activity of the undigested bactofencin A/SBA-15 and bactofencin 
A/MSE samples inhibited growth by 87 % and 69 % respectively. SBA-15 appears to offer the highest 
degree of protection for bactofencin, most likely due to its slow release of the peptide. The bacteriocin 
may lodge inside the pore structure of the mesoporous matrices which the protease is too large to 
access. The estimated dimensions of trypsin are 51Å x 41Å x 41Å (Mallen and Hudson 2017) (Guinane 
et al. 2016) which is similar size to the pores of both SBA-15 and MSE, therefore trypsin is most likely 
to block the pores of the matrix and will be unable to diffuse far down the pores of SBA-15 or MSE to 
where the bactofencin A is adsorbed. It may also be protected as long as it is absorbed on the surface 
of the matrix through steric hindrance of the protease to the target basic residues in the bacteriocin. 
Thus it has been shown how the use of mesoporous silicates (unfunctionalised and organo-bridged) 
as delivery matrices protects the peptide from proteolysis while preserving and possibly enhancing its 
antibacterial properties. 
Biocompatibility of mesoporous matrices
  
The biocompatibility of the matrices was examined using HEK293 cells. Cells were grown in the 
presence of increasing concentrations of the MPS (1, 3 & 5 mg/mL) for 3 different incubation times (2, 
6 & 24 hours). MTT results revealed slight differences in biocompatibility between the two materials. 
The concentrations of SBA-15 tested showed ~ 10% decrease in cell viability after 2 hours incubation 
at the higher concentrations tested whereas after 6 hours incubation there was evidence of cell 
proliferation as cell viability exceeded 100% when compared to the control (Figure 7). Decrease in cell 
viability after exposure to MSE was slightly higher, where ~ 30-40% decrease in cell viability was 
evident after 2 hours. However, viability of HEK cells after 6 & 24 hours was >80%. Similar results for 
the biocompatibility of SBA-15 were seen by Hudson et al. where the viability of macrophages exposed 
to various different unfunctionalised and functionalised MPS decreased by ~20% or less. However % 
cell viability after exposure to the mesoporous matrices with mesothelial cells was much lower (≤40%) 
at the highest concentration tested (0.5mg/mL) (Hudson et al. 2008). Concentrations of SBA-15 tested 
during that study were 10 fold lower compared to this work. Overall MSE appeared to have a slightly 
more cytotoxic effect on cell survival than SBA-15. The biocompatibility of these organo-bridged 
matrices has not been previously reported but the data shown here would suggest that the 
introduction of bridged organic species has some effect on cell viability. It’s widely reported that these 
mesoporous materials are biocompatible both in vitro and in vivo and once their function has been 
exhausted, they can be secreted by the body (Tang et al. 2012). Similar results on the biocompatibility 
of SBA-15 were reported previously where cell (macrophage) survival decreased (down to 80%) at 
concentrations of 0.3 and 0.5mg/mL after 3 days incubation. However, during this study cell survival 
fell below this value under the same conditions for mesothelial and C2C12 muscle cells (Hudson et al. 
2008). Other studies also confirm the biocompatible nature of various MPS matrices but size, surface 
properties, shape and structure all influence its cytotoxic properties (Tang et al. 2012, Esquivel et al. 
2014, Du et al. 2016). After 24 hours for all concentrations tested, viability returned to ~80% and 
therefore no prolonged damage to cells was noted. 
Conclusion 
Bactofencin A could potentially be used a new antibiotic that could be brought to the market. This 
study demonstrates that by protecting bactofencin A in a mesoporous matrix, its inherent activity 
against S. aureus was improved. In addition, upon exposure to a protease, bactofencin A retained far 
more activity when in a mesoporous matrix compared to as a free peptide in solution. Bactofencin A 
was found to preferentially bind to a more hydrophilic surface than a hydrophobic surface but in 
previous studies with a more hydrophobic bacteriocin, nisin, preferential adsorption was observed to 
a more hydrophobic surface. This study highlights the possibility of oral delivery of peptides using a 
  
traditional and an organo-bridged mesoporous silicate due to high drug loadings, enhanced 
antibacterial properties, biocompatibility and enzymatic stability. The anaerobic environment in the 
gut varies hugely from in vitro tests where all assays are performed in aerobic conditions, so it is unclear 
how the administration of antimicrobial peptides may affect overall microbial gut balance. Therefore 
in vivo testing would be recommended as the next step to this development. While the use of these 
delivery matrices is promising, in silico studies looking at surface functional group and peptide and 
pore size complementarity between the peptide and the protective matrix would enable a systemic 
selection of a mesoporous matrix for an individual bacteriocin with potential antimicrobial therapeutic 
properties.
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Figure list
Figure 1 Figure 1. (a) % of bactofencin A loaded onto MSE (grey bar) & SBA-15 (black bar) after 2 
hours incubation.
*Figure 2.  (a) % and (b) concentration (µg/ml) of bactofencin A released from MSE over 24 hours 
into PBS. Results are average of duplicate on two random testing days with standard deviation. No 
release of bactofencin A was detected from SBA-15.
Figure 3. MIC50 for bactofencin A against S. aureus at concentrations 5, 3, 2, 1 & 0.5 ug/ml, compared 
to a control (no peptide). All values are means of 6 values ± standard deviation. Bactofencin A was 
incubated with S. aureus culture in a 96 well plates for 37ºC x 24hours. Results include averages of 
two random tests of triplicates with standard deviations.
Figure 4. Inhibition of S. aureus growth by Bactofencin A loaded SBA-15 (5.47 mg added, 0.47 mg 
bactofencin) and MSE (5.17 mg added, 0.17 mg bactofencin) and free Bactofencin A (0.5 mg) after 5 
hours incubation. Results include averages of two random tests of duplicates with standard 
deviations.
Figure 5. HPLC chromatogram of Bactofencin A (0.8mg/ml) and Bactofencin A (0.8mg/ml) incubated 
with (a) trypsin and (b) proteinase K overnight at 37ºC.
Figure 6. Activity of bactofencin A loaded onto SBA-15 (dotted bar) & MSE (grey bar) & free 
bactofencin A (striped bar) treated overnight with trypsin against S. aureus. Results are expressed in 
CFU/ml. Control was set up with culture only (black bar). Results include averages of two random 
tests of duplicates with standard deviations.
Figure 7. % Viability of Human Embryonic Kidney (HEK293) cells when incubated for up to 24 hours 
with SBA-15 and MSE. Live controls were set up and results were expressed as 100%, all other 
results were normalised to the live controls.
  
*All single column fitting except for figure 2 which is 2-column fitting.
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